Microbiotica

Brainomix, a global leader and pioneer of AI-powered imaging biomarkers for stroke and lung fibrosis, has announced results from its partnership with Argenica Therapeutics for imaging and clinical data analysis of the Phase II trial evaluating ARG-007, a neuroprotective agent for acute ischemic stroke.

NRG Therapeutics, an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the appointment of Paul Thompson PhD as Chief Development Officer (CDO).

Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the appointment of four world leading experts to its Scientific Advisory Board (SAB).

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that Dr Robert Tansley is appointed Chief Medical Officer with immediate effect.

Myricx Bio (‘Myricx’), a private biotech company focusing on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), is scaling ahead of entering the clinic and is pleased to announce the appointment of Boston-based Mohit Rawat as its Chief Executive Officer (CEO) and member of the Board of Directors.

NRG Therapeutics, an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B financing.

Microbiotica announces positive results in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.

Microbiotica announces that patient recruitment is complete in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.

Microbiotica has presented new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC), at Digestive Disease Week (DDW) 3rd – 6th May in San Diego.

Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage mediated antifibrotic therapy.

Brainomix is set to launch its new Brainomix 360 Next Generation platform at the International Stroke Conference (ISC).

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that patient recruitment is complete in its advanced melanoma (MELODY-1) trial.

Microbiotica has presented new data on the mechanism of action of MB097 at the American Association for Cancer Research (AACR) annual meeting held in Chicago, April 25-30.

Brainomix, a global leader in AI-powered imaging solutions in stroke and lung fibrosis, has announced the appointment of Anna Griffin as Chief Financial Officer, filling a key leadership role within the company following its recent £14 million Series C funding round.

Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, has garnered widespread media attention1 this week following a renewed focus on the impact of its Brainomix 360 Stroke technology to improve recovery rates for stroke patients.

Microbiotica announces that the first patient has been dosed in its advanced melanoma (MELODY-1) trial. This international trial is due to recruit up to 40 patients at clinical centres in the UK, France, Italy and Spain. Initial data readouts are expected by the end of 2025.

Brainomix 360 Stroke has been deployed in all 25 sites, marking the first time the entire WVU network has access to a unified AI solution to support faster and more consistent acute stroke decision-making.

Microbiotica to Present Positive Update on Manufacturing Progress of its Live Biotherapeutic Products for Forthcoming Melanoma and Ulcerative Colitis Clinical Studies

Brainomix has published a prospective real-world study demonstrating that its AI imaging platform, Brainomix 360 Stroke, significantly increased rates of endovascular thrombectomy (EVT) treatment.

Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce the appointment of David Ellis, PhD, in the newly created position of VP, Regulatory Affairs, based in the USA.

Brainomix has been selected by Boehringer Ingelheim, the leading biopharmaceutical company providing therapeutic options for interstitial lung disease (ILD).

Company secures additional financing to advance clinical programmes in Immuno-Oncology and Inflammatory bowel disease through to data readout

Microbiotica announces that the first patient has been dosed in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.